https://www.nasdaq.com/press-release/bellerophon-reports-positive-top-line-data-from-phase-2-acute-dose-escalation-study
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-third-quarter-2021-financial
https://www.nasdaq.com/press-release/bellerophon-to-present-at-the-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-second-quarter-2021
https://www.nasdaq.com/press-release/bellerophon-to-present-at-the-jefferies-virtual-healthcare-conference-2021-05-27
https://www.nasdaq.com/press-release/bellerophon-appoints-naseem-amin-m.d.-as-chairman-of-its-board-of-directors-2021-05
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-first-quarter-2021-financial
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-fourth-quarter-and-full-0
https://www.nasdaq.com/press-release/bellerophon-to-present-at-the-h.c.-wainwright-global-life-sciences-conference-2021-03
https://www.nasdaq.com/press-release/bellerophon-to-present-at-the-h.c.-wainwright-virtual-bioconnect-2021-conference-2021
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-first-patient-enrolled-in-phase-3-rebuild-study
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-results-of-interim-analysis-of-phase-3-covinox
https://www.nasdaq.com/press-release/bellerophon-to-present-at-the-h.c.-wainwright-6th-annual-israel-conference-2020-11-11
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-third-quarter-2020-financial
https://www.nasdaq.com/press-release/bellerophon-to-present-results-from-its-phase-2-ino-pf-study-of-inopulser-for-the
https://www.nasdaq.com/press-release/bellerophon-to-present-at-two-september-investor-conferences-2020-09-14
https://www.nasdaq.com/press-release/bellerophon-appoints-cardiopulmonary-disease-expert-wassim-fares-m.d.-mscr-as-chief
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-second-quarter-2020
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-publication-of-cohort-1-of-ino-pf-phase-2-3-study
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-first-patient-treated-in-phase-3-clinical-study-of
https://www.nasdaq.com/press-release/bellerophon-therapeutics-added-to-russell-3000r-and-microcapr-indexes-2020-06-29
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-closing-of-%2443.7-million-public-offering-of-common
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-pricing-of-public-offering-of-common-stock-and
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-proposed-public-offering-of-common-stock-2020-05
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-first-quarter-2020-financial
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-fda-clears-initiation-of-phase-3-study-for
https://www.nasdaq.com/press-release/bellerophon-therapeutics-to-participate-in-covid-19-panel-at-maxim-groups-infectious
https://www.nasdaq.com/press-release/bellerophon-therapeutics-submits-investigational-new-drug-application-to-study
https://www.nasdaq.com/press-release/bellerophon-provides-clinical-program-update-and-reports-fourth-quarter-and-full-year
https://www.nasdaq.com/press-release/bellerophon-announces-closing-of-%2415.3-million-registered-direct-offering-of-common
https://www.nasdaq.com/press-release/bellerophon-therapeutics-to-host-investor-call-and-webcast-today-on-inopulser-for-the
https://www.nasdaq.com/press-release/bellerophon-announces-%2415.3-million-registered-direct-offering-priced-at-the-market
https://www.nasdaq.com/press-release/bellerophon-therapeutics-announces-first-patient-treated-with-inopulser-inhaled
https://www.nasdaq.com/press-release/fda-grants-bellerophon-emergency-expanded-access-for-inopulser-for-the-treatment-of
https://www.nasdaq.com/press-release/bellerophon-announces-agreement-with-the-fda-on-its-planned-pivotal-phase-3-study-for
https://www.nasdaq.com/press-release/bellerophon-reports-positive-top-line-data-from-an-ancillary-acute-hemodynamic-study
https://www.nasdaq.com/press-release/bellerophon-announces-1-for-15-reverse-stock-split-2020-02-07
https://www.nasdaq.com/press-release/bellerophon-announces-positive-top-line-results-from-cohort-2-of-phase-2-3-study-of
https://www.nasdaq.com/press-release/bellerophon-announces-positive-initial-data-from-acute-hemodynamic-dose-escalation
https://www.nasdaq.com/press-release/bellerophon-presents-new-data-from-cohort-1-of-ongoing-phase-2-3-study-of-inopulser
